Atlas Venture Opportunity Fund II, L.P. has filed a notice to sell 2,388 shares of common stock in Disc Medicine, Inc. This filing, made on October 20, 2026, is significant as it highlights the ongoing activity and strategic decisions within the pharmaceutical preparations sector.
Disc Medicine, Inc. operates under the Central Index Key (CIK) 0001816736 and is classified under the pharmaceutical preparations industry. The company has undergone name changes in recent years, previously operating as Gemini Therapeutics, Inc. and FS Development Corp. The filing indicates that the shares were acquired through a private placement on May 1, 2020, for cash.
The filing states, "Atlas Venture Opportunity Fund II, LP is a shareholder of Disc Medicine, Inc., and is looking to sell a portion of its holdings." The aggregate market value of the shares being sold is approximately $188,484.84, with the shares set to be sold through Merrill Lynch, a well-known broker.
This move may affect investor sentiment towards Disc Medicine and similar biotech firms, as it reflects a strategic exit by a significant shareholder. The pharmaceutical industry remains competitive, with other players like Gemini Therapeutics, Inc. and FS Development Corp. also vying for investor attention.
As for what’s next, the filing does not specify any further actions or upcoming filings related to this transaction. Investors and analysts will be keen to see how this sale impacts the stock performance of Disc Medicine, Inc. and the broader market dynamics in the pharmaceutical sector.